Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY INDUSTRY

2.1 Summary about Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry

2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends

2.2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Production & Consumption Trends

2.2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Demand Structure Trends

2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Glassia

4.2.2 Aralast NP

4.2.3 Prolastin C

4.2.4 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospitals

4.3.2 Specialty Clinics

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Glassia

5.2.2 Aralast NP

5.2.3 Prolastin C

5.2.4 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospitals

5.3.2 Specialty Clinics

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Glassia

6.2.2 Aralast NP

6.2.3 Prolastin C

6.2.4 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospitals

6.3.2 Specialty Clinics

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Glassia

7.2.2 Aralast NP

7.2.3 Prolastin C

7.2.4 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospitals

7.3.2 Specialty Clinics

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Glassia

8.2.2 Aralast NP

8.2.3 Prolastin C

8.2.4 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospitals

8.3.2 Specialty Clinics

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Glassia

9.2.2 Aralast NP

9.2.3 Prolastin C

9.2.4 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospitals

9.3.2 Specialty Clinics

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Grifols

10.1.2 CSL

10.1.3 Baxter

10.1.4 Kamada

10.1.5 Takeda

10.1.6 Abeona

10.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Sales Date of Major Players (2017-2020e)

10.2.1 Grifols

10.2.2 CSL

10.2.3 Baxter

10.2.4 Kamada

10.2.5 Takeda

10.2.6 Abeona

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Type Overview

2.Table Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Type Market Share List

3.Table Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Type of Major Players

4.Table Brief Introduction of Grifols

5.Table Brief Introduction of CSL

6.Table Brief Introduction of Baxter

7.Table Brief Introduction of Kamada

8.Table Brief Introduction of Takeda

9.Table Brief Introduction of Abeona

10.Table Products & Services of Grifols

11.Table Products & Services of CSL

12.Table Products & Services of Baxter

13.Table Products & Services of Kamada

14.Table Products & Services of Takeda

15.Table Products & Services of Abeona

16.Table Market Distribution of Major Players

17.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

18.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

19.Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (Million USD) by Region 2021f-2026f

20.Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (Million USD) Share by Region 2021f-2026f

21.Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (Million USD) by Demand 2021f-2026f

22.Table Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Forecast (Million USD) Share by Demand 2021f-2026f